Efficacy and Tolerability of Hypericum Extract WS 5572 versus Placebo in Mildly to Moderately Depressed Patients

We have investigated the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS 5572 in a double-blind, placebo-controlled multicenter clinical trial. 72 patients (WS 5572: 37, placebo: 35) with a diagnosis of mild to moderate major depressive disorder (according to DSM-IV criteria) were randomized in 42 days of treatment with either 300 mg WS 5572 t. i. d. or placebo. The primary efficacy variable was the change of the 17-item Hamilton Depression Scale (HAMD) total score between baseline and double-blind treatment. The study was conducted with an adaptive interim analysis, which led to early stopping because convincing treatment efficacy could already be demonstrated. Group differences in favor of WS 5572 were descriptively apparent as early as day 7 of randomized treatment and were statistically significant at days 28 (p = 0.011) and day 42 (p < 0.001). Between baseline and treatment end, the HAMD total score decreased from 19.7 ± 3.4 to 8.9 ± 4.3 points in the Hypericum group and from 20.1 ± 2.6 to 14.4 ± 6.8 points in the placebo group (mean ± SD). Responder rates were consistently higher in the Hypericum group. Comparable group differences in favor of WS 5572 were also found for von Zerssen's Depression Scale (D-S; self-rating), Clinical Global Impressions (CGI) and a global patient's self-assessment (GPA). Tolerability was very good in both groups, with no adverse drug reactions and no clinically relevant changes in safety parameters. The results indicate that Hypericum extract WS 5572 is an effective and well-tolerated drug for the treatment of mild to moderate major depressive disorder.

References

• 1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders, 4^th Edition (DSM-IV). Washington, D.C; American Psychiatric Association 1994
• 2 Angst J. How recurrent and predictable is depressive illness?. In: Montgomerys S, Rouillion F, editors Longterm treatment of depression. New York; Wiley 1992: 1-13
• 3 Bauer R, Köhne K. Evaluation of experiments with adaptive interim analyses.  Biometrics. 1994;  50 1029-1041
• 4 Collegium Internationale Psychiatriae Scalarum (CIPS) .Internationale Skalen fur die Psychiatrie, 4^th edition. Göttingen; Beltz 1996
• 5 Demisch L, Hölzl J, Gollnik B, Kaczmarczyk P. Identification of selective MAO-type-A inhibitors in Hypericum perforatum (Hyperforat). (Abstr.).  Pharmacopsychiat. 1989;  22 194
• 6 De Smet P A G M, Nolen W A. St. John's wort as an antidepressant.  BMJ. 1996;  313 241-242
• 7 Dilling H, Weyerer S. Psychische Erkrankungen in der Bevölkerung bei Erwachsenen und Jugendlichen. In: Dilling H, Weyerer S, Castell R, editors Psychische Erkrankungen in der Bevölkerung. Stuttgart; Enke 1994: 1-121
• 8 Ernst E. St. John's wort, an anti-depressant? A systematic, criteria-based review.  Phytomedicine. 1995;  2 67-71
• 9 Friede T, Kieser M, Miller F. Modeling the recovery from depressive illness by an exponential model with mixed effects.  Methods Inf Med. 2000;  39 12-15
• 10 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 62-66
• 11 Judd L. Mood disorders in the general population represent an important and worldwide public health problem.  Int Clin Psychopharmacol. 1995;  10 ((Suppl. 4)) 5-10
• 12 Kasper S, Kasper A. Langzeitbehandlung affektiver Störungen.  Nervenarzt. 1994;  65 577-589
• 13 Kieser M. Biometrischer Bericht der geplanten adaptiven Interim-analyse einer randomisierten placebokontrollierten Doppelblindstudie zum Nachweis der klinischen Wirksamkeit und der Verträglichkeit von Hypericum-Extrakt, bei leicht- bis mittelgradigen depressiven Episoden. Unpublished report. Karlsruhe, Germany Dr. Willmar Schwabe Pharmaceuticals 1997
• 14 Kieser M, Bauer P, Lehmacher W. Inference on multiple endpoints in clinical trials with adaptive interim analyses.  Biometr J. 1999;  41 261-277
• 15 Laakmann G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.  Pharmacopsychiat. 1998;  31 (Suppl.) 54-59
• 16 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John' wort for depression - an overview and meta-analysis of randomized clinical trials.  BMJ. 1996;  313 253-258
• 17 Linden M, Maier W, Achberger M, Herr R, Helmchen H, Benkert O. Psychiatric diseases and their treatment in general practice in Germany. Results of a World Health Organization (WHO) study [Article in German].  Nervenarzt. 1996;  67 205-215
• 18 McLean P D, Hakistan A R. Relative endurance of unipolar depression treatment effect: longitudinal follow-up.  J Consult din Psychol. 1990;  58 482-488
• 19 Müller W E, Rolli M, Schäfer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity.  Pharmacopsychiat. 1997;  30 (Suppl.) 102-107
• 20 National Institute of Mental Health .Clinical Global Impressions (CGI). In: Guy W, editor EDCEU assessment in psychopharmacology, rev. ed. Rockville, MD: US Department of Health, Education and Welfare 1970: 217-222
• 21 Noether G E. Sample size determination for some nonparametric tests.  J Amer Statist Assoc. 1987;  82 645-647
• 22 Pathare S R, Paton C. ABC of mental health Psychotropic drug treatment.  BMJ. 1997;  315 661-664
• 23 Priest R G, Hawley C J, Kibel D, Kurian T, Montgomery S A, Patel A G. et al . Recovery from depressive illness does fit an exponential model.  J Clin Psychopharmacol. 1996;  16 420-424
• 24 Schatzberg A F, Kraemer H C. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression.  Society of Biological Psychiatry. 2000;  47 736-744
• 25 Schmidt U, Sommer H. Johanniskraut zur ambulanten Therapie der Depression.  Fortschr Med. 1993;  111 339-342
• 26 Schulz H, Jobert M. Der Einfluss von Johanniskraut-Extrakt auf das Schlaf-EEG bei älteren Probandinnen.  Nervenheilkunde. 1993;  12 232-327
• 27 Schütt H, Schulz V. Hypericum. In: Hansel R, Keller K, Rimpler H, Schneider G, editors Hagers Handbuch der Pharmazeutischen Praxis, Vol. 5: Drogen E-0. Berlin: Springer 1993: 476-495
• 28 Song F, Freemantle N, Sheldon T A, House A, Watson P, Long A, Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.  BMJ. 1993;  306 683-687
• 29 Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin.  Planta Med. 1984;  50 272-274
• 30 Thase M E, Simons A D, McGeary J N, Cahalane J F, Hughes C, Handen T, Friedman E. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment.  Am J Psychiatry. 1992;  149 1046-1052
• 31 Volz H P. Controlled clinical trials of Hypericum extracts in depressed patients - an overview.  Pharmacopsychiat. 1997;  30 (Suppl) 102-107
• 32 Von Zerssen D, Strian F, Schwarz D. Evaluation of depressive states, especially in longitudinal studies. In: Pichot P, Oliver-Martin R, editors Psychological measurements in psychopharmacology, Vol. 7. Basel, Munich, Paris: Karger 1974: 189-202

1 WS 5572 complies with the criteria defined for standardized Hypericum extracts in the literature. The extract is contained in the German pharmaceutic product Neuroplant® 300